A5001467929- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- RNA modifications and cancer
- Peroxisome Proliferator-Activated Receptors
- Ferroptosis and cancer prognosis
- CAR-T cell therapy research
- RNA Interference and Gene Delivery
- Virus-based gene therapy research
Shanghai Jiao Tong University
2022-2024
Shanghai Ninth People's Hospital
2022-2024
Second-generation androgen receptor (AR) inhibitors such as enzalutamide are the first-line treatments for castration-resistant prostate cancer (CRPC). Resistance to will greatly increase difficulty of treatment and reduce survival time patients. However, drug-resistant cells seem be more sensitive ferroptosis. Therefore, we constructed a biomimetic tumor-targeting magnetic lipid nanoparticle (t-ML) codeliver dihomo-γ-linolenic acid (DGLA) 2,4-dienoyl-CoA reductase 1 (DECR1) siRNA...
Drug resistance is an important factor for prostate cancer (PCa) to progress into refractory PCa, and abnormal lipid metabolism usually occurs in which presents great challenges PCa therapy. Here, a cluster of differentiation 36 (CD36) inhibitor sulfosuccinimidyl oleate sodium (CD36i) stearoyl-CoA desaturase 1 (SCD1) siRNA (siSCD1) are selected inhibit uptake synthesis respectively. To this end, multiresponsive drug delivery nanosystem, HA@CD36i-TR@siSCD1 designed. The hyaluronic acid (HA)...